CMPX
Compass Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing antibody-based therapies for cancer and autoimmune disease, working on programs such as bispecific antibodies and antibody-drug conjugates. It grew out of Boston's biotech ecosystem, founded by drug-development scientists in the early 2010s to build a pipeline of novel antibody medicines aimed at solid tumors. The company takes its name from the guiding idea of using antibodies to "point" the immune system, like a compass, toward cancer cells — a naming quirk that frames its whole mission.
CUSIP: 20454B104HealthcareUS1 holder
Total Value
$2.72M
Total Shares
514.8K
Net Share Change
+514.8K
Activity
1 buying
Investor
Value
Shares
Weight
Change
